EGFR and non-small cell lung carcinoma: However, Shimamura et al (2005) recently reported that certain EGFR kinase domain mutations which occur in a sub-population of non-small cell lung cancer (NSCLC) and which enhance sensitivity to EGFR inhibitors, also conferred dependence on Hsp90 and resulted in acquired sensitivity of the mature protein to Hsp90 inhibition.